NEW YORK (GenomeWeb News) – CLC Bio today said that it has signed a distribution agreement for its next generation sequencing solutions in Japan.
The Aarhus, Denmark-based firm has signed Filgen as a reseller of its products in the Japanese market.
CLC Bio also named David Leangen as CEO of its CLC Bio Japan business.
"In 2009 we have experienced a considerable increase of interest in our solutions from Japan," Michael Heltzen, director of partner sales at CLC bio, said in a statement. "This is logically linked with the significant increase of Next Generation Sequencing instruments being installed, which in turn requires analysis capacity of the huge amounts of data - an area where we excel."